- Previous Close
0.2400 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.5300 - Volume
0 - Avg. Volume
9,034 - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
-0.00 - EPS (TTM)
-0.0590 - Earnings Date Oct 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. In addition, it provides Sunrise, a bio-signal to diagnose sleep apnea. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
somnomed.com/au/--
Full Time Employees
June 30
Fiscal Year Ends
--
Sector
--
Industry
Recent News: SOM.XA
View MorePerformance Overview: SOM.XA
Trailing total returns as of 11/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SOM.XA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SOM.XA
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-13.36%
Return on Assets (ttm)
-7.86%
Return on Equity (ttm)
-36.31%
Revenue (ttm)
91.65M
Net Income Avi to Common (ttm)
-12.24M
Diluted EPS (ttm)
-0.0590
Balance Sheet and Cash Flow
Total Cash (mrq)
16.18M
Total Debt/Equity (mrq)
14.93%
Levered Free Cash Flow (ttm)
-6.86M